A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Thyroid"
DOI: 10.1089/thy.2022.0027
Abstract: Background: Cabozantinib inhibits pathways involved in medullary thyroid cancer (MTC). Cabozantinib is approved as 140 mg/day in capsules for MTC and 60 mg/day in tablets for other solid tumors. This study compared the two doses in progressive… read more here.
Keywords: day; per day; 140 day; progressive metastatic ... See more keywords